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Abstract: Closed-globe injury can cause visual loss in military and civilian populations, with retinal
cell death, including retinal ganglion cell (RGC) degeneration, leading to irreversible blindness. RGC
and optic nerve (ON) degeneration after eye or head injury is termed traumatic optic neuropathy
(TON). There are currently no treatments for RGC loss, therefore novel therapeutics to prevent
RGC death or promote axonal regeneration are a priority. We investigated necroptotic signaling
mechanisms in a rat blunt ocular injury model. After bilateral blunt trauma, protein expression and
retinal localization of necroptosis pathway members (receptor interacting protein kinase 1, RIPK1;
receptor interacting protein kinase 3, RIPK3; and mixed lineage kinase domain like pseudokinase,
MLKL) were assessed by Western blot and immunohistochemistry (IHC), and potent necroptosis
inhibitor Necrostatin-1s (Nec-1s) was delivered by intravitreal injection to one eye and vehicle to
the contralateral eye. RGC and photoreceptor survival were assessed by cell counting and outer
nuclear layer (ONL) thickness measurements on histology. The neuroprotective effects of Nec-1s
were assessed in primary retinal culture by βIII-tubulin+ RGC cell counts. MLKL protein expression
were upregulated at 48 h after injury and MLKL immunolocalised to retinal binding protein with
multiple splice (RBPMS)+ RGC, inner nuclear cells and ONL cells, specifically at the retinal injury
site. RIPK3 expression did not increase but RIPK3 co-immunolocalised with RBPMS+ RGC in intact
and injured retinae. In vitro, a Nec-1s concentration of 0.01 pg/µL was RGC neuroprotective. In the
blunt ocular injury rat model, Nec-1s prevented RGC death at the center of the impact site but did not
protect against ONL thinning or provide functional restitution. RGC degeneration in our blunt ocular
injury model is site-specific, with necroptosis driving death at the center of the focal impact site.
Keywords: necroptosis; retinal ganglion cells; cell death; trauma; traumatic optic neuropathy; commotio
retinae; photoreceptors
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1. Introduction
Ocular injuries are common, occurring in 10% of all military casualties [1] and have a lifetime
prevalence of 20% in the civilian population [2]. The light-sensitive membrane at the posterior portion
of the eye, the retina, contains many cells including photoreceptors and retinal ganglion cells (RGC),
which convert light into electrical signals and relay this information to the brain for processing. RGC
exist in the ganglion cell layer (GCL) and their axons form the brain connection from the eye to the brain,
the optic nerve (ON). The retina is an extension of the central nervous system (CNS), which means that if
retinal cells, including photoreceptors and RGC, are injured and lost through disease or injury, they are
not endogenously replaced. Thus, their preservation is important to prevent irreversible loss of vision.
Traumatic optic neuropathy (TON) can be caused by head or eye injury and is associated with RGC
and axonal degeneration, causing irreversible blindness [3,4]. The ON can be injured either directly
(e.g., penetrating ocular injury, bony fragment damage with optic canal, and ON sheath hematomas)
or indirectly after traumatic head or eye injury (e.g., blunt eye injury and blast) [5–7]. Blunt ocular
injury causes injury to RGC and photoreceptors (commotio retinae) [8]. There are currently no effective
treatments for TON [9], despite TON occurring with an annual incidence of at least 1/1,000,000 in the
civilian population [10], and in up to 20% of military eye injuries [11]. TON can be studied using
animal models replicating blunt and blast ocular injuries [12–15] and ON crush (ONC) [16–18].
Necroptosis (controlled necrosis) is a regulated cell death pathway resulting in cell leakage,
organelle swelling, cytoplasmic granulation and the initiation of an inflammatory response [19,20].
Receptor-interacting protein kinase 1 (RIPK1) and 3 (RIPK3) are essential in tumor necrosis factor
(TNF)-induced necroptosis. After TNF stimulation at the TNF receptor, complex I is formed, which
involves polyubiquitinated RIPK1 and activation of the pro-survival NF-κβ pathway [21]. Reduced
pro-survival signals lead to complex I dissociation and the formation of complex IIa, which normally
causes apoptosis. However, if caspase-8 activation is inhibited, either through endogenous or
pharmacological inhibitors, then RIPK1 and RIPK3 associate alongside mixed lineage kinase domain-like
(MLKL) and form complex IIb. RIPK3 phosphorylates MLKL at Ser345 [22], inducing its translocation
to the plasma membrane, triggering membrane permeabilization and necroptotic death [23].
Necroptosis promotes neuronal cell death in trauma, neurodegeneration and eye disease [24]. RIPK1
expression is elevated in a rat intracerebral hemorrhage model and its inhibition or genetic knockdown
reduces brain injury severity [25]. Further, in a mouse model of Alzheimer’s disease (APP/PS1 mice)
treatment with necroptosis inhibitor Necrostatin-1 (Nec-1) reduces cognitive impairments, β-amyloid
and tau abnormalities [26]. Nec-1 also improves histopathology and function in models of traumatic
brain and spinal cord injury [27,28]. In a retinal ischemia-reperfusion model, there is increased expression
of RIPK1 and RIPK3 and inactive caspase-8 present in the GCL and Nec-1 administration reduced
retinal damage and provided RGC neuroprotection in vivo and in vitro [29,30]. However, Nec-1 has
some off-target effects, as it also inhibits indoleamine-2,3-dioxygenase (IDO), which has a role in
immunomodulatory function [30]. Therefore, in this study we used an alternative more stable analogue
called Necrostatin-1 stable (Nec-1s), which has higher affinity and specificity than Nec-1, is >1000 fold
more selective for RIPK1 than other human kinases and does not interfere with IDO [31,32].
Previously, we have shown that RGC die by caspase-2-dependent mechanisms in the peripheral
portion of the focal retinal impact site, but we did not identify the mechanisms of RGC death at
the center of the impact site, where there is the greatest RGC death [33]. Blanch et al., have also
demonstrated that caspase-9 promotes photoreceptor death and a lack of caspase-8 activation after
blunt ocular injury, implying that necroptotic mechanisms could have been activated in this model [34].
In this current study, we have demonstrated necroptotic death occurring in the retina at early time
points in a blunt ocular injury rat model and inhibition of necroptosis by Nec-1s prevents some RGC
death at the center of the impact site but did not provide functional RGC protection.
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2. Materials and Methods
2.1. Experimental Design
To determine the role of necroptosis in RGC and photoreceptor death after blunt ocular injury,
groups of adult female adult Lister Hooded rats were subjected to unilateral or bilateral blunt ocular
injury under anesthesia, as previously described [15]. Western blot and immunohistochemistry were
performed at 5, 24 and 48 h after injury to determine RIPK1, RIPK3 and MLKL retinal protein levels and
cellular localization (Figure 1A). Nec-1s, a selective necroptosis inhibitor, was used to manipulate RGC
survival in primary retinal cultures in vitro and in a rat blunt ocular injury model in vivo (Figure 1B).
RGC and photoreceptor functional and structural assessments were performed using scotopic and
photopic electroretinogram (ERG) recordings, and the number of retinal binding protein with multiple
splicing (RBPMS)+ and brain-specific homeobox/POU domain protein 3A (BRN3A)+ RGC counted,
and outer nuclear layer (ONL) thickness measured in retinal sections.
2.2. Animal Care and Procedures
Animal procedures were licensed by the UK Home Office, approved by the University of
Birmingham’s Animal Welfare and Ethical Review Committees and conducted in accordance with the
ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Female Lister-hooded
rats, weighing 180–220 g, were purchased from Charles River Laboratories (Margate, UK), kept on a
12 h light–dark cycle with a daytime luminance of 80 lux and fed and watered ad libitum. Surgery
and ERG recordings were performed under inhalational anesthesia with 2–3% isoflurane in oxygen.
Blunt ocular injury was induced as previously described [15]. Briefly, a 0.095 g spherical plastic pellet
was fired using compressed air to directly impact the inferior scleral surface at a speed of 20 m/s. This
creates a localized retinal injury-causing photoreceptor and RGC degeneration by 14 days post injury
(dpi) and extensive loss of retinal function, with ERG amplitude reduced to <50% of intact values [15].Cells 2019, 8, x FOR PEER REVIEW 4 of 23 
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Figure 1. Experimental design. (A) In vivo protein and immunofluorescent staining studies; (B) In vivo
Nec-1s study. Abbreviations: DMSO = Dimethyl Sulfoxide; ERG = electroretinogram; MLKL = mixed
lineage kinase domain-like; Nec-1s = Cecrostatin-1s; PBS = phosphate buffered saline; RIPK1 = receptor
interacting protein kinase 1; RIPK3 = receptor interacting protein kinase 3.
2.3. Western Blot
Rats were killed at 5, 24 and 48 h after bilateral blunt ocular injury, as well as uninjured intact
controls, by overdose of anesthetic (six pooled retinas from three animals receiving bilateral blunt
injury and re eate on at least two independent occasi ns). Protein extraction and Western blot were
performed as previously described [35]. Briefly, retinal proteins were extracted in ice- old lysis buffer
supplemented with pr teas inhibitor cocktail (Sigma, Poole, UK). Protein extr cts w re d natured
by h ating to 90 ◦C for 5 min and 40 µg of prot in/lane was s parat d on 12% Tri -glycine sodium
dodecyl sulphate (SDS) gels, transferred o po yvinylid ne fluoride (PVDF) membranes (M ll pore,
Watford, UK), probed with appropriate primary and secondary antibodies (Table 1) and specific protein
bands were detected using chemiluminescence by exposure to photographic film (GE Healthcare, Little
Chalfont, UK). Blots were repeated on at least two independent occasions. Integrated band intensity
was measured using the built-in gel analysis macros in Fiji Image J [36] and displayed as % of loading
control (β-actin). Error bars represent standard error of the mean (SEM).
2.4. Intravitreal Injection of Nec-1s
Nec-1s (Bio Vision Incorporated, CA, USA) was reconstituted at 3.6 mM in 10% dimethyl sulfoxide
(DMSO) and 0.9% methyl-β-cyclodextrin (Sigma) in sterile phosphate buffered saline (PBS). Bilateral
blunt ocular injury was performed and 5 µL of Nec-1s administered by unilateral intravitreal injection
and 5 µL of vehicle (10% DMSO, 0.9% methyl-β-cyclodextrin in PBS) was injected into the contralateral
eye. Injections were performed immediately after injury and at 7 dpi until culling and tissue collection at
14 dpi (n = eight eyes/treatment, eight animals total). Uninjured animals were culled without intravitreal
injections as intact controls (n = eight animals). Animals were intracardially perfused under terminal
anesthesia and eyes processed for immunohistochemistry.
2.5. Tissue Preparation for Immunohistochemistry
Tissues were prepared for immunohistochemistry as previously described [33]. Briefly, at 5 and
48 h after unilateral blunt injury (n = four rats per experimental group), rats were killed by overdose of
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anesthetic and intracardially perfused with 4% paraformaldehyde (PFA) in PBS. The anterior segment
was removed and small cuts to identify the injury site were made prior to cryoprotection in a graded
series of sucrose solution. Tissues were embedded in optimal cutting temperature compound (OCTc),
sectioned in a plane parallel to that running between the injury site and the optic disc at a thickness of
15 µm using a cryostat (Brights Instruments, Huntingdon, UK) and adhered onto SuperFrostTM (Fisher
Scientific, Loughborough, UK) coated glass microscope slides, and stored at −20 ◦C until required.
2.6. Immunohistochemistry Protocol
Frozen sections were left to thaw for 20 min and washed 3 × 5 min in PBS, followed by 20 min
permeabilization and blocking non-specific sites in PBS containing 1% Triton-X-100 (Sigma) and 3%
bovine serum albumin (BSA; Sigma). Sections were incubated overnight at 4 ◦C with appropriate
primary antibodies (Table 1) in 0.5% Tween-20 and 3% BSA, before washing 3 × 5 min in PBS
and incubating with relevant secondary antibodies (Table 1) at room temperature (RT). Sections
were washed 3 × 5 min in PBS and then mounted in Vectashield mounting medium containing
4′,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Peterborough, UK). Controls with omitted
primary antibody were included in each run and these were used to set the background threshold
levels prior to image capture. Sections were viewed under an AxioPlan 2 epi-fluorescent microscope
equipped with an AxioCam HRc, controlled using Axiovision Software (all from Zeiss, Hertfordshire,
UK). Images were captured and analyzed by an investigator masked to the treatment conditions.
Table 1. List of primary and secondary antibodies used for western blot (WB) and immunohistochemistry (IHC).
Antigen (Origin) Dilutions Company Catalogue Number
RIPK1 (mouse) 1:200 (WB) BD Pharmigen 551041
RIPK3 (B2) (mouse) 1:200 (IHC) Santa Cruz SC374639
RIPK3 (rabbit) 1:1000 (WB) Abcam AB56164
MLKL (rat) 1:5000 (WB),1:1000 (IHC) Millipore MABC604
BRN3A (C-20) (goat) 1:200 (IHC) Santa Cruz SC-31984
RBPMS (rabbit) 1:400 (IHC) Millipore ABN1362
β-actin (mouse) 1: 10,000 (WB) Sigma A5441
βIII-tubulin (mouse) 1:200 (ICC) Sigma T8660
Secondary Antibodies (Origin) Dilutions Company Catalogue Number
Anti-goat Alexa Fluor 594 (goat) 1:400 (IHC) Invitrogen A11058
Anti-rabbit Alexa Fluor 488 (donkey) 1:400 (IHC) Invitrogen A21206
Anti-rabbit Alexa Fluor 594 (donkey) 1:400 (IHC) Invitrogen A21207
Anti-rat Alexa Fluor 488 (goat) 0.736111 Invitrogen A11006
Anti-rabbit HRP-linked (goat) 1:1000 (WB) Cell Signalling Technologies 7074S
Anti-rat HRP-linked (goat) 1:5000 (WB) Cell Signalling Technologies 7077S
Anti-mouse HRP-linked (horse) 1:1000 (WB) Cell Signalling Technologies 7076S
2.7. Electroretinography (ERG)
ERG were recorded (HMsERG—Ocuscience, Kansas City, MO, USA) at 7 and 14 dpi and in
uninjured controls and were interpreted using ERG View (Ocuscience). Animals were dark-adapted
overnight and prepared for ERG under dim red light (>630 nm). Scotopic (dark-adapted) flash ERG
were recorded from −2.5 to +1 log units with respect to standard flash in half log unit steps and
photopic (light-adapted) flash ERG were recorded with background illumination of 30,000 mcd/m2
over the same range. DTL fiber (Unimed Electrode Supplies, Farnham, UK) corneal electrodes with
pressure-molded Aclar (Agar scientific, Stansted, UK) contact lenses were used with needle skin
electrodes (Unimed). ERG traces were analyzed using the manufacturer’s semi-automated software
ERG View (Ocuscience) and marker position manually verified and adjusted where necessary by a
masked observer. Photopic negative response (PhNR) was recorded as a measure of RGC function.
2.8. Assessment of ONL Thickness
Animals were culled at 14 dpi and eyes processed as for immunohistochemistry. ONL thickness
was measured by a masked observer, as previously described, to determine photoreceptor survival [34].
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Briefly, seven retinal sagittal sections per eye, stained with Hematoxylin and Eosin (H&E), were
analyzed (to account for variability with respect to distance from the impact site) through the optic
nerve head (ONH) and center of the impact site (0 µm) and at 600, 1200 and 1800 µm either side of
this plane. Sections were scanned using a Zeiss AxioScan Z1 slide scanner and the ONL manually
segmented in Adobe Photoshop by a masked observer, and the ONL area was divided by the length of
the retinal segment to give an average ONL thickness in pixels.
2.9. Assessment of RGC Survival
RGC survival was quantified using immunohistochemistry for BRN3A [37,38] and RBPMS [39,40].
The number of BRN3A+ and RBPMS+ immunostained RGC were counted by a masked observer, in
the GCL across the entire retinal section. Seven retinal sagittal sections per eye were counted: at the
optic disc and center of the impact site (0 µm), and at 600, 1200 and 1800 µm to either side of this plane,
and quantified as the number of BRN3A+ or RBPMS+ RGC per mm of retina.
2.10. Primary RGC Culture and Immunocytochemistry
Adult 6–8 week-old Sprague Dawley rats (170–220 g; Charles River) were killed by overdose
of anesthetics and retinae dissected and dissociated into single cells with a Papain dissociation kit
(Worthington Biochem, NJ, USA) [35]. A density of 125,000 retinal cells, containing enriched populations
of RGC, were plated per well in 8-well chamber slides (BD Biosciences) pre-coated with 100 µg/mL
poly-D-lysine and 10 µg/mL laminin. Cells were incubated in 300 µL of supplemented Neurobasal-A
(Invitrogen) containing 2% v/v B27 supplement (Life Technologies, Invitrogen), 0.5 mM L-glutamine
(Invitrogen) and 0.5% v/v Gentamycin (50 mg/mL Invitrogen), at 37 ◦C in 95% O2 and 5% CO2. After
1-day incubation, 200 µL of supplemented media containing various concentrations of Nec-1s was added
to the wells, to make a final concentration of 0.01–100 pg/µL of Nec-1s in 500 µL of media. Cells were
then fixed with 4% PFA in PBS, blocked in 0.1% Triton-X-100, incubated in primary antibody solution
(Table 1) in antibody diluting buffer (0.5% Tween-20, 3% BSA in PBS) followed by incubation with
secondary antibody both for 1 h at RT. Slides were washed in PBS mounted with Vectashield mounting
media containing DAPI (Vector Laboratories Ltd.), and imaged using the AxioPlan 2 epi-fluorescent
microscope (Carl Zeiss). RGC were stained using βIII-tubulin, a neuronal marker which labels all
retinal neurons in the mixed culture (bipolar cells, interneurons), and not specifically RGC [41–43], and
45 images per well randomly imaged, and βIII-tubulin+ RGC (small round cells with a DAPI stained
nucleus and green βIII-tubulin staining in the cytoplasm and have one axon) counted and displayed as
average number of βIII-tubulin+ RGC per mm2. Primary retinal cultures were performed in duplicate
and repeated on three independent occasions.
2.11. Statistics
Power calculations performed in G*Power (v. 3.1.4, Kiel University, Germany) indicated for
Western blotting, n = three animals per time point had 82% power to detect a 1-fold change in protein
levels, (assuming standard deviation = 20% band intensity); for ERG assessment (more variable than
structural measures, therefore less powerful) eight animals had a power of 88% to detect a moderate
(f = 0.25) treatment effect (correlation among repeated measures = 0.5 from past data) [15].
Statistical analysis was carried out using SPSS (IBM Corp, Armonk, NY, USA) and GraphPad
Prism version 7.00. (GraphPad Software, La Jolla California). The data were tested for normality
using the Shapiro–Wilk test. Western blot data were analyzed using one-way analysis of variance
(ANOVA) and post-hoc Tukey tests with p values corrected for multiple comparisons. In experiments
where multiple comparisons were made, the p values were corrected with Bonferroni correction and
the correction factor is stated. ERG amplitudes, BRN3A+ and RBPMS+ RGC count data and ONL
thicknesses were analyzed using generalized estimating equations (autoregressive correlation matrix,
gamma distribution with log link). Data are reported as mean ± standard error of the mean (SEM).
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3. Results
3.1. MLKL Protein Expression was Higher 5 h after Blunt Ocular Injury Compared with Intact Eyes, but
RIPK1 and RIPK3 Expression Did Not Change
We first determined if the expression of key necroptotic proteins, RIPK1 and RIPK3 as well as
downstream MLKL, were altered in our blunt ocular trauma model by performing bilateral blunt
ocular injury collecting retinal tissue for immunofluorescent staining and Western blot at 5, 24 and 48 h
after injury, as well as from separate intact control animals. Protein expression of RIPK1, RIPK3, MLKL
were investigated using Western blot (n = three animals per experimental group, six pooled retinae,
repeated on at least two independent occasions). Representative blots are shown in Figure 2A,C,E, and
densitometry of band intensities in Figure 2B,D,F.Cells 2019, 8, x FOR PEER REVIEW 8 of 23 
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Figure 2. Receptor interacting protein kinase 1 (RIPK1), receptor interacting protein kinase 3 (RIPK3)
and Mixed Lineage Kinase Domain like Pseudokinase (MLKL) protein expression after blunt ocular
injury. Representative Westerns blot with β-actin as a loading control. (A,B) RIPK1 showed no changes
in in protein expression after blunt ocular injury (p = 0.494, ANOVA). (C,D) RIPK3 protein expression
remained constant after injury (p = 0.677, ANOVA). (E,F) MLKL protein expression significantly
increased at 5, 24 and 48 h after blunt ocular injury (p < 0.0001, ANOVA, post-hoc Tukey *** p < 0.0001,
* p < 0.05). Blots represent six pooled retina, from three animals receiving bilateral blunt injury and
repeated on at least two independent occasions. Error bars represent mean ± SEM.
There was strong evidence of an increase in retinal MLKL expression at 5, 24 and 48 h after blunt
ocular injury (p < 0.0001, ANOVA; Figure 2E,F), with a band intensity compared to β-actin peaking
at 1.033 ± 0.035 24 h after injury (13.8-fold increase from intact; Tukey’s post hoc t-test p < 0.0001).
We observed that the levels of RIPK1 in the retina increased at 5, 24 and 48 h after blunt ocular
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injury compared to levels in intact controls by Western blot (Figure 2A) but subsequent densitometry
(Figure 2B) showed no changes (p = 0.494, ANOVA). The levels of RIPK3 remained unchanged
(p = 0.677, ANOVA; Figure 2C,D).
These results show that MLKL was significantly upregulated in the retina after blunt ocular
trauma, which is a key step in necroptosis.
3.2. RIPK3 is Localized to BRN3A+ RGC whilst MLKL is Localized to OPL, ONL, INL and RBPMS+ RGC
We then used immunofluorescent staining to determine the localization of RIPK3 and MLKL
in the retina. RIPK3 showed co-localization with the RGC-specific marker, BRN3A and its staining
intensity and localization appeared to be unchanged after blunt ocular trauma when compared to
intact eyes (Figure 3A). MLKL immunofluorescence was elevated in cells at the focal impact site at 48 h
post injury (Figure 3B), but not at 5 (Figure 3B) or 24 h, as shown in a composite image of the entire
retina, with elevated expression mainly in the photoreceptor inner segments, outer plexiform layer
(OPL) as well as some ONL cells, inner nuclear layer (INL) cells and RBPMS+ RGC (Figure 3C).
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Figure 3. Immunofluorescent staining showed that receptor interacting protein kinase 3 (RIPK3) expression
was no dif nt at the focal impact site 48 h after blunt ocular injury compared wi h control eyes but
Mixed Lineage Kinase Domain like Pseudokinase (MLKL) expression was higher. Images are taken from
the same region of the injury site (representative of n = 4). (A) RIPK3 immunostaining was no different in
Brain-specific homeobox/POU domain protein 3A (BRN3A)+ retinal ganglion cells (RGC) in the ganglion
cell layer (GCL) t 5, 24 and 48 h ft r blunt cular inju y. (B) MLKL prot in expr ssion was low in intact
eyes and 5 and 24 h after injury, but higher 48 h fter i jury and localized to the outer plexiform layer
(OPL) as well as some outer nuclear layer (ONL) cells, inner nuclear layer (INL) cells and retinal binding
protein with multiple splicing (RBPMS)+ RGC in the GCL. (C) Composite image of a retina 48 h after blunt
injury. Immunostaining shows MLKL expression is localized specifically to the blunt ocular injury site.
Nuclei wer counterstained with DAPI (blue). Scale bar in Figure 3A represents 20 µm and Figure 3B
represents 50 µm. Images are represe tative of n = four animals.
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3.3. Nec-1s is Neuroprotective In Vitro
To determine the contribution of necroptosis to RGC death in vitro, we used a specific, stable
inhibitor of RIPK1 to inhibit necroptosis and measured RGC death in adult primary mixed retinal
cultures (Figure 4A). Representative βIII-tubulin+ immunostained retinal cultures are shown in
Figure 4B, with RGC highlighted with a white arrow. Retinal cultures were treated with a concentration
of 100 to 0.01 pg/µL of Nec-1s and showed significant neuroprotection of βIII-tubulin+ RGC (p < 0.05,
ANOVA; Figure 4B,C). The statistical effect of treatment was driven by 0.01 pg/µL Nec-1s, which
caused a ~1.5-fold increase in βIII-tubulin+ RGC (p < 0.05, ANOVA, post-hoc Tukey with multiple
comparisons p = 0.03; Figure 4C). At high concentrations Nec-1s (10–100 pg/µL), the number of
βIII-tubulin+ RGC was similar to vehicle-treated cultures. These results demonstrate that Nec-1s is
significantly neuroprotective to RGC in culture.
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Figure 4. The number of β-III-Tubulin+ retinal ganglion cells (RGC) was higher after Necrostatin-1s
(Nec-1s) treatment compared to vehicle in primary rat mixed retinal cultures. Treatment with varying
doses of Nec-1s were performed in duplicate and performed on three independent occasions. (A) The
experimental design of retinal culture experiments with Nec-1s treatment. Cells were plated at a 125,000
cell density in 300 µL supplemented media, after 1 day 200 µL of supplemented media containing
Nec-1s was added, to make final concentrations of 0.01 to 100 pg/µL Nec-1s. (B) Representative images
of β-III-Tubulin+ RGC (white arrow heads) treated with 100 to 0.01 pg/µL of Nec-1s. (C) The number of
β-III-Tubulin+ RGC were quantified by taking 45 images per well, and displayed as mean percentages
of vehicle controls. Nec-1s provided significant protection of β-III-Tubulin+ RGC compared to vehicle
control treatment (PBS, 10% DMSO, 0.9% β-methyl-cyclodextrin). In Figure 4B, the scale bar represents
100 µm. Values are mean ± SEM.
3.4. Nec-1s Preserved BRN3A+ and RBPMS+ RGC at the Center of the Blunt Injury Site Compared to Vehicle
Treated Eyes but did not Preserve Photoreceptors
We then determined the contribution of necroptosis to RGC death after blunt ocular trauma
in vivo. Bilateral blunt ocular injury was performed with unilateral intravitreal injection of Nec-1s and
contralateral vehicle injection (n = eight eyes per condition, eight/ animals). The number of BRN3A+
(Figure 5A) and RBPMS+ (Figure 5B) RGC were quantified at varying distances from the center of the
impact site (0, 600, 1200 and 1800 µm).
Nec-1s treated eyes had a greater number of BRN3A+ and RBPMS+ RGC at the center of the
impact site compared to vehicle controls, with an effect that varied by distance from the impact site
(GLM for BRN3A [p < 0.001] and RBPMS [p = 0.04] counts), with little effect of Nec-1s on the number of
BRN3A+ and RBPMS+ RGC at distances more peripheral from the impact site (600, 1200 and 1800 µm;
Figure 5A,B; model output in Table 2A,B). At the center of the impact site, there were 72.05% of RBPMS+
RGC in Nec-1s treated eyes, compared to 60.56% in vehicle treated eyes, and 77.64% BRN3A+ stained
RGC in Nec-1s treated eyes, compared to 63.27% in vehicle treated control eyes.
Photoreceptor survival was assessed by ONL thickness measurements on H&E stained retinal
sections at 600, 1200 and 1800µm either side of the impact site (Figure 5C), as previously described [33,34].
There was no significant effect on ONL thickness in Nec-1s injected eyes compared to vehicle control,
with no significant variation by distance from impact site (generalized estimating equations p = 0.313;
model output in Table 2C). The normalized ONL thickness at 0, 600, 1200 and 1800 µm from impact
site were 53.92%, 53.45%, 45.19% and 57.02% of intact retinae in Nec-1s treated eyes, compared to
47.36%, 47.09%, 43.4% and 53.30% in vehicle treated control eyes. Collectively, these results suggest
that inhibition of the necroptotic pathway specifically protects RGC after blunt ocular trauma, but
not photoreceptors.
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Figure 5. Necrostatin-1s (Nec-1s) treatment is protective of Brain-specific homeobox/POU domain
protein 3A (BRN3A) + and retinal binding protein with multiple splicing (RBPMS)+ retinal ganglion
cells (RGC) at the center of the impact site but does not preserve outer nuclear layer (ONL) thickness.
(A,B) The number of BRN3A+ and RBPMS+ RGC were counted across entire retinal sections and
reported as the number of RGC per mm of retina. Animals received bilateral blunt ocular injury with
unilateral Nec-1s treatment and contralateral vehicle control. After unilateral intravitreal injection of
Nec-1s, the number of BRN3A+ and RBPMS+ RGC was higher compared to vehicle control-treated
eyes, across the retina with respect to retinal position (generalized linear models; BRN3A p < 0.01,
RBPMS p < 0.05), likely driven by larger numbers of RGC detected at the center of the injury site. In the
distant periphery (1200 µm, 1800 µm), there was less retinal degeneration overall and no significant
effect of Nec-1s treatment on the number of BRN3A+ or RBPMS+ RGC compared to vehicle. (C) ONL
thickness was reduced after blunt ocular injury and Nec-1s treatment did not preserve ONL thickness
compared to vehicle control (generalized linear models; p = 0.313). Error bars represent mean ± SEM. n
= 8 per group (intact = eight animals, n = eight bilateral blunt injured with unilateral Nec-1s intravitreal
injection and contralateral vehicle intravitreal injection).
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Table 2. Mean number of Brain-specific homeobox/POU domain protein 3A (BRN3A)+ and retinal
binding protein with multiple splicing (RBPMS)+ retinal ganglion cells (RGC) and outer nuclear
layer (ONL) thickness after blunt ocular injury and treatment with Necrostatin-1s (Nec-1s) injections.
(A,B) BRN3A+ and RBPMS+ RGC counts in intact animals and after blunt ocular injury treated with
Nec- 1s or vehicle intravitreal injections. The values represent the mean number of BRN3A+ or RBPMS+
RGC per mm of retina (95% confidence intervals). (C) ONL thickness in intact animals and after blunt
ocular injury treated with Nec-1s or vehicle intravitreal injections. Values are mean pixels of ONL
(95% confidence intervals).
A Mean Number of BRN3A+ RGC per mm of Retina (95% CI)
Treatment 0 µm 600 µm 1200 µm 1800 µm
Intact
56.95 59.87 57.48 63.10
(52.7–61.2) (56.2–63.5) (51.7–63.3) (42.2–74.0)
Blunt + Nec-1s
44.2 44.7 49.3 54.7
(39.1–50.0) (35.9–55.6) (36.9–65.9) (39.5–75.9)
Blunt + vehicle
36.0 41.0 48.1 56.8
(27.0–48.2) (24.8–67.8) (25.4–91.3) (27.4–118)
p value for comparison p = 0.017 n/a n/a n/a
B Mean Number of RBPMS+ RGC per mm of Retina (95% CI)
Treatment 0 µm 600 µm 1200 µm 1800 µm
Intact
62.68 64.70 63.84 72.16
(58.2–67.2) (60.7–68.7) (58.0–69.7) (61.3–83.6)
Blunt + Nec-1s
45.2 46.9 51.8 58.9
(40.4–50.5)0 (37.9–57.9) (39.6–67.8) (44.7–77.6)
Blunt + vehicle
38.0 43.6 50.5 60.9
(29.3–49.1) (27.4–69.3) (29.0–87.9) (33.0–112.6)
p value for comparison p = 0.02 n/a n/a n/a
C Mean Number of Pixels of ONL Thickness (95% CI)
Treatment 0 µm 600 µm 1200 µm 1800 µm
Intact
98.12 101.72 120.66 144.34
(94.4–101.9) (94.1–109.4) (104.9–136.4) (125.6–163.1)
Blunt + Nec-1s
52.91 54.36 54.53 82.31
(45.1–60.7) (45.5–63.3) (47.6–61.5) (76.8–87.8)
Blunt + vehicle
46.47 47.90 52.38 76.79
(36.6–56.3) (42.0–53.7) (42.5–62.3) (69.0–93.5)
p value for comparison p = 0.229 p = 0.292 p = 0.625 p = 0.143
3.5. Nec-1s Treatment did not Preserve ERG Amplitudes After Blunt Ocular Injury
We then determined if RGC neuroprotection close to the injury site led to preservation of RGC
function. Scotopic and photopic ERG recordings were performed at 14 dpi and compared to between
Nec-1s and vehicle-treated eyes (n = eight animals) to assess retinal function. Intact animals receiving
no injections were also analyzed (n = eight animals). There were reductions in the PhNR (Figure 6A),
photopic b-wave (Figure 6B), scotopic a-wave (Figure 6C) and scotopic b-wave (Figure 6D) amplitudes
after blunt ocular injury compared to intact animals, but there was no improvement in amplitudes in
Nec-1s treatment eyes compared to vehicle treated eyes (Figure 6A–D). These results demonstrate that,
although more RGC were neuroprotected after treatment with Nec-1s, compared to intact eyes their
function was still impaired.
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Figure 6. There were no differences in electroretinogram (ERG) amplitudes in Necrostatin-1s (Nec-1s)
treated eyes compared to vehicle treated eyes after blunt ocular injury. (A) Photopic negative response
(PhNR) amplitudes were reduced after blunt ocular injury and PhNR amplitudes were not increased
by Nec-1s treatment compared to vehicle control. (B) Scotopic b-wave; (C) scotopic a wave and; (D)
photopic b-wave amplitudes were reduced after blunt ocular injury and there was no improvement
with Nec-1s treatment compared to vehicle control. Error bars represent mean ± SEM. n = eight per
group (intact = eight animals, n = eight bilateral blunt injured with unilateral Nec-1s intravitreal
injection and contralateral vehicle intravitreal injection).
4. Discussion
We have shown elevated retinal levels of necroptosis pathway proteins, including MLKL in RGC
and other retinal cells. We further show that treatment with a necroptosis inhibitor, Nec-1s, was
neuroprotective to RGC in vitro and prevented RGC loss at the center of the impact site in a rat model
of closed-globe blunt ocular injury in vivo.
MLKL protein expression was higher after blunt ocular injury compared with intact retina, but
we did not detect changes in RIPK1 or RIPK3 protein levels. RIPK3 was localized to BRN3A+ RGC,
although there were no significant changes in protein levels up to 48 h after injury, suggesting that
RIPK3 levels were not altered by injury. The lack of RIPK3 upregulation, despite other features of
necroptosis being present, may relate to the post-translational nature of RIPK activation or the existence
of RIPK3-independent pathways [44]. MLKL immunostaining, however, was localized to cells in
the OPL, INL, ONL and RGC at 48 h after blunt injury at the center of the impact site, suggesting
that multiple retinal cell types, including photoreceptors, may have upregulated MLKL expression,
and hence activated necroptotic signaling pathways. MLKL had the greatest increase in protein
expression at 24 h in Western blotting, but no immunostaining until 48 h, which may be explained
by differences in detection technique. Western blotting runs denatured proteins on an SDS-gel after
separating protein complexes (e.g., necrosome) and opening protein structure, while PFA fixation used
for immunostaining provides a snapshot of proteins in a fixed state and with intact protein complexes.
Cells 2019, 8, 1517 14 of 21
During necroptosis, MLKL complexes with RIP1 and RIP3 in complex IIb, leading to phosphorylation
of the pseudokinase domain (adjacent to the “brace” region recognized by our antibody [45]), which
induces its oligomerization and translocation to the plasma membrane. The epitope recognized by
our antibody may therefore have been blocked in complex IIb and more readily recognized after
phosphorylation, oligomerization and plasma membrane translocation, meaning that we detected
increased MLKL protein levels and its epitope earlier in the course of MLKL production and activity
by Western blotting because of the open structure of the protein in this technique, but only later
by immunohistochemistry after conformational and binding changes. Necroptotic photoreceptor
death occurs in in vivo models of retinal detachment and age-related macular degeneration [46,47],
suggesting that necroptosis may also drive photoreceptor degeneration after blunt ocular injury.
The phosphorylation of MLKL at Ser345 is catalyzed by RIPK1 and promotes MLKL translocation
and accumulation at the plasma membrane, inducing membrane permeabilisation and cell lysis [22,23],
although the association of RIPK3 and MLKL in the necrosome is not dependent on Ser345
phosphorylation [22]. We have shown MLKL expression is upregulated 24–48 h after injury.
Immunofluorescent staining in the OPL suggests that MLKL is present in the connections between the
photoreceptors and INL cells.
For necroptotic signaling to be activated and induce cell death, apoptotic caspase-8 must be
inhibited either through endogenous or pharmacological inhibitors or remain uncleaved. This allows for
the formation of complex IIb and the association of RIPK1, RIPK3 and MLKL [20]. Blanch et al., showed
that caspase-8 remained uncleaved up to 48 h after blunt ocular injury [34], with no retinal caspase-8
immunostaining and unbiased caspase-capture experiments using b-VAD-fmk, confirming that there was
no caspase-8 activation since no cleaved caspase-8 was isolated, indicating that caspase-8-independent
cell death signaling drives retinal cell death after blunt ocular injury [34].
RIPK1 is a key mediator of necroptotic cell death, but not exclusively, and also has roles in
apoptotic and inflammatory pathways [44]. Similarly, MLKL can have roles in death-receptor-induced
apoptosis [48] and inflammasome activation [49,50]. We detected no changes in RIPK1 protein
expression after blunt ocular injury up to 48 h, but we do show increased MLKL specifically at the
focal impact site. Blanch et al., have shown no retinal activation of apoptotic caspase-8, implying that
the extrinsic apoptotic pathway is not occurring in the retina after injury. This is consistent with our
previous studies demonstrating that intrinsic caspase-9 dependent and the non-canonical caspase-2
dependent pathways drive a proportion of retinal death in the blunt ocular injury model [33,34,51].
The necroptosis inhibitor, Nec-1s, is a synthetic allosteric inhibitor of RIPK1 and inhibits necroptotic cell
death through preventing the transition from Complex IIa to Complex IIb, by inhibiting the interaction
of RIPK1 and RIPK3 [21,52,53].
After ON injury, RGC death begins within 5 days and there is >90% RGC loss at 14 dpi [16].
Adult RGC begin to die in retinal cultures due to the disrupted RGC axonal connections. Previous
studies have used the same timeframe for retinal cultures and shown effective results from a variety
of treatments [42,43]. There was a significant neuroprotective effect in culture after Nec-1s treatment
compared to vehicle control, suggesting that necroptosis signaling mediates the death of a proportion
of RGC. At low doses of Nec-1s (0.01 pg/µL), there was significant improvement in RGC numbers, but
at higher doses (100 pg/µL) there was no RGC neuroprotection, indicating that low concentrations
of Nec-1s may be more effective in vitro. Neuroprotection in vitro in primary retinal cell cultures
indicates that necroptotic cell death pathways can mediate degeneration of injured RGC but does not
take into account drug clearance and metabolism and immune response. However, as necroptosis
can be linked to inflammation [54,55], primary retinal cultures are, therefore, not fully representative
of in vivo signaling pathways, but provide a screening platform to identify RGC neuroprotective
agents [35,41,42,56,57]. At lower concentrations of Nec-1s, necroptosis might be reduced rather than
fully inhibited, which might be more beneficial. Cell death pathways are interlinked and, if one
pathway is reduced, another might be activated, for example, inhibition of caspase-8 dependent
apoptosis promotes necroptosis [58]. DMSO is used to solubilize the compounds but can be neurotoxic
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to RGC at high concentrations. For example, in vitro, concentrations of >10% DMSO induce RGC
apoptosis and plasma membrane pore formation [59,60]. We reconstituted Nec-1s in 10% DMSO and
0.9% methyl-β-cyclodextrin to aid with solubility. Despite the potential of DMSO to cause RGC death
at higher concentrations, we have shown consistent retinal pathology across studies, suggesting DMSO
had a minimal effect in our study [15,33,34].
Our in vivo rat blunt ocular injury model induces retinal cell death in a focal area, causing
photoreceptor death and RGC degeneration [15,33,34]. We previously proposed that RGC death
is driven by caspase-2 in the immediate periphery (600 µm) to the center of the impact site, and
now propose that necroptosis drives RGC death at the center of the impact site. In our previous
publication, small interfering RNA (siRNA)-mediated caspase-2 knockdown protected a proportion
of RGC and preserved electroretinographic RGC function [33]. In the immediate periphery of the
impact site, siRNA-mediated caspase-2 knock preserved 85% of BRN3A+ RGC compared to 67% in
siEGFP-treated blunt injured eyes, suggesting that 18% of RGC in this region degenerated by a process
of caspase-2 dependent apoptosis. siCASP2 had no detectable effect on RGC survival at the impact site
center [33], despite preserving >98% RGC in the ONC model [61], suggesting that other cell death
pathways mediate RGC degeneration after blunt ocular injury at the center of the impact site. Electron
microscopic evidence suggests that injury is most severe at the center of the impact site, with more
extensive cell death and necrotic, rather than apoptotic morphology [15]. We propose that RGC death
in the center of the impact site, is mediated by necroptotic mechanisms, evidenced by elevated MLKL
and increased numbers of RGC compared to vehicle control in this region. After Nec-1s injection, 78%
of BRN3A+ RGC were preserved in the center of the impact site, compared to 63% after control vehicle
injection, suggesting that 15% of RGC in this region undergo necroptotic cell death. We did not observe
any evidence of necroptotic death outside the center of the impact site, and in our previous paper we
only observed evidence of caspase 2-dependent RGC death in the region peripheral to the impact site
and none at the impact site center. This implies that caspase-2 and necroptotic death pathways occur
simultaneously in the same cell type but in different regions of the impact site, probably related to the
severity of injury at the different locations (Figure 7). However, Nec-1s (or siCASP2 [33]) treatment did
not preserve the number of RGC to levels found in intact retina, suggesting that whilst some RGC
degeneration was mediated by necroptotic signaling pathways, a proportion of RGC death at the
center of the impact site occurs through other pathways, such as uncontrolled necrosis.
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to untreated control eyes. Our previous publication showed caspase-2 drives RGC death in the
immediate periphery of the impact site. Uncontrolled necrosis is likely to occur throughout the impact
site, due to the impact of the blunt projectile.
Cells 2019, 8, 1517 16 of 21
In line with our findings, RGC are also protected by the inhibition of necroptosis in other models
of RGC death, including glaucoma [62] and retinal ischemia-reperfusion injury [63], and other models
of neuronal disease and degeneration, including amyotrophic lateral sclerosis [64–66], Alzheimer’s
disease [26], Niemann–Pick disease [67], traumatic brain injury [28] and spinal cord injury [27].
The abundance of studies across multiple disease indicates the importance of necroptotic signaling in
driving neuronal cell death.
Caspase-2 can negatively regulate necroptosis, and downregulation of caspase-2 using shRNA
or CRISPR/Cas9 system enhances phosphorylation of RIPK1 and MLKL [68]. In our studies,
siCASP2-mediated knock down improved RGC survival, but the number of preserved RGC might have
been underrepresented; if caspase-2 suppression caused necroptosis activation this could have caused
death in some RGC, limiting the neuroprotective efficacy of siCASP2. The converse is unlikely to be
true, as we are not aware of any data suggesting modulation of caspase-dependent death by necroptotic
mechanisms. Furthermore, apoptotic and necroptosis death mechanisms can occur simultaneously in
the same cell type [69], consistent with the observations that both caspase-2 and necroptotic-dependent
death occur simultaneously in our model.
RGC were quantified by counting BRN3A+ (RGC-specific transcription factor with nuclear
immunostaining) and RBPMS+ (cytoplasmic marker) immunostained cells in the GCL [37,70]. BRN3A
only stains a subset of RGC and its expression can be reduced after RGC injury [38,71,72]. RBPMS
immunolabels a greater proportion of RGC subpopulations [39,40], but has yet to be validated as a
reliable RGC marker [37]. Nonetheless, we demonstrated significant RGC neuroprotection using both
BRN3A and RBPMS markers after Nec-1s treatment following blunt ocular injury, with similar cell
counts by both methods.
Photoreceptor cell bodies populate the ONL; therefore, ONL thickness can be used to assess
photoreceptor survival [15,34]. In the rd10 mouse retinitis pigmentosa model, inhibition of RIPK1 using
Nec-1 or ripk3 gene knockout preserved cone photoreceptors and function [73], and photoreceptor
necroptosis also occurs in models of age-related macular degeneration [74] and a model of retinal
detachment [46]. As an alternative to intravitreal injections, Nec-1s was delivered through subcutaneous
delivery and rescued ONL thinning in a mouse P23H rhodopsin model of retinal degeneration [75],
suggesting that Nec-1s can have an effect in the retina through systemic and non-local delivery. In the
blunt ocular injury model, intrinsic apoptotic pathway member caspase-9 mediates degeneration of
some photoreceptors in the far periphery of the impact site and caspase-9 inhibition using a dominant
negative mutant protein preserved ERG amplitudes [34]. Despite the immunolocalization of MLKL to
the ONL, OPL and photoreceptor inner segments, treatment with Nec-1s did not preserve of ONL
thickness compared to vehicle, which could be explained by (1) necroptosis not mediating photoreceptor
death after blunt injury or; (2) necroptosis inhibition promoting activation of an alternative cell death
signaling pathway.
Scotopic (dark-adapted) and photopic (light-adapted) ERG amplitudes were measured to assess
retinal function. The PhNR is a common measure of RGC function; it is reduced in experimental and
human glaucoma [76] and correlates with reduced RGC numbers after ON transection [77]. Treatment
with Nec-1s had no effect on scotopic or phototopic a- or b- wave amplitudes and did not affect
PhNR amplitudes, suggesting that retinal function, including photoreceptor and RGC function, was
not improved by Nec-1s treatment. The lack of functional restitution suggests that some RGC are
structurally protected by Nec-1s but may be non-functional, thus detecting no differences in PhNR
amplitude. It is also possible that the focal nature of the retinal injury and the specific neuroprotection of
RGC at the center of the impact site may mean that too few RGC are preserved and functional enough to
be detectable by full-field ERG. Focal changes in retinal function may be more sensitively detected using
focal or pattern ERG in future investigations. The complete absence of any trend towards improved
function on ERG suggests that this is not the case, and a reduction in PhNR amplitude with blunt injury
despite the focal impact also discourages this explanation.
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5. Conclusions
In conclusion, we have demonstrated that RGC death signaling pathways are active in a
region-specific manner after blunt ocular injury, with necroptotic-dependent mechanisms likely
driving a reduction in RGC numbers at the center of the impact site. The inhibition of necroptosis using
pharmacological inhibitor, Nec-1s, preserved the number of RBPMS+ and BRN3A+ RGC compared to
vehicle. This suggests that Nec-1s might protect a proportion of RGC, but, as there was no increase in
ERG amplitudes, Nec-1s did not provide any corresponding improvement in retinal function. We have
previously shown that caspase-2-dependent RGC death occurred peripheral to the impact site, which,
collectively with this study, suggests that multiple cell death signaling pathways can occur in parallel
in the same tissue and in the same cell type, in a single injury model.
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